Ren Luo is listed as a director on 4 SEC Form D filings by 1 issuer between Aug 2020 and Jun 2022: AnPac Bio-Medical Science Co., Ltd. (Lishui, China (as filed: F4) — biotechnology — 2020–2022; $1.5M reported sold to 1 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Feng Guo (4 shared filings), He Yu (4 shared filings), Pu Xing (4 shared filings), Weidong Dai (4 shared filings), XueDong Du (4 shared filings) and 11 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ren. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Ren Luo and found 2 differences: Form D filed 17 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.